7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
6 citations
,
April 2024 in “Health Science Reports” Younger patients with severe alopecia areata often have nail problems.
6 citations
,
September 2022 in “Vaccines” Some people developed alopecia areata after COVID-19 vaccination, but it's not caused by the vaccine and most improved with treatment.
5 citations
,
September 2023 in “Clinical Cosmetic and Investigational Dermatology” Patients with Alopecia Areata often have higher anxiety and depression.
5 citations
,
March 2023 in “International Journal of Trichology” Alopecia areata patients may have higher cardiovascular risk factors, so screening for metabolic syndrome components is suggested.
3 citations
,
July 2023 in “International Journal of Trichology” DPCP can help regrow hair in some people with severe alopecia.
3 citations
,
June 2023 in “Frontiers in Medicine” A new model uses specific blood markers to predict if children's hair loss will return.
3 citations
,
October 2022 in “Journal of Cosmetic Dermatology” CAR is a useful marker for assessing alopecia areata severity.
2 citations
,
February 2024 in “Indian Dermatology Online Journal” Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
1 citations
,
May 2023 in “Journal of the American Academy of Dermatology” Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
February 2026 in “Biomedicines” Off-label treatments are heavily used for alopecia areata due to limited approved options.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
January 2026 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deep-learning models can effectively diagnose and assess Alopecia areata using scalp images.
January 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” High levels of HSP70 and IL-15 are linked to more severe alopecia areata.
November 2025 in “Medicina” Alopecia areata may be linked to changes in body fat but not to heart or artery issues.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
August 2025 in “Indian Dermatology Online Journal” Both treatments work equally well for hair regrowth, but the lotion has fewer side effects.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
April 2025 in “Annals of Medicine” Compound glycyrrhizin with conventional treatments is effective and safe for hair regrowth in alopecia areata.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.